ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea
· Delayed Price · Currency is KRW 11,020
+630 (6.06%)
At close: Dec 5, 2025
ImmuneOncia Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Net Income | -20,520 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade
|
| Depreciation & Amortization | 1,051 | 1,051 | 1,031 | 1,081 | 1,026 | 956.83 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0.77 | 1.38 | 3.18 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | - | 9.39 | Upgrade
|
| Stock-Based Compensation | 981.9 | 981.9 | 1,311 | 3,991 | 1,948 | 472.34 | Upgrade
|
| Other Operating Activities | -743.81 | -5,975 | -19,648 | -10,767 | 48,945 | 7,143 | Upgrade
|
| Change in Accounts Receivable | -410.83 | -410.83 | 622.65 | -710.85 | - | - | Upgrade
|
| Change in Unearned Revenue | - | - | - | -4,952 | 6,884 | 18.62 | Upgrade
|
| Change in Other Net Operating Assets | 1,059 | -4,623 | -518.09 | -452.73 | -292.68 | 269.6 | Upgrade
|
| Operating Cash Flow | -18,583 | -14,663 | -8,337 | -15,301 | -1,976 | -10,288 | Upgrade
|
| Capital Expenditures | -48.58 | -86.87 | -428.43 | -36.21 | -101.34 | -34.34 | Upgrade
|
| Sale (Purchase) of Intangibles | -141.23 | -52.09 | - | -52.4 | -4.85 | -9.06 | Upgrade
|
| Investment in Securities | -12,000 | 1,900 | -5,000 | 6,000 | 2,708 | 16,506 | Upgrade
|
| Other Investing Activities | -684 | -32.6 | 96.71 | -8.47 | -840 | -13.8 | Upgrade
|
| Investing Cash Flow | -12,874 | 1,728 | -5,332 | 5,903 | 1,762 | 16,449 | Upgrade
|
| Long-Term Debt Repaid | - | -55.79 | -103.65 | -232.1 | -210.93 | -183.37 | Upgrade
|
| Net Debt Issued (Repaid) | -62 | -55.79 | -103.65 | -232.1 | -210.93 | -183.37 | Upgrade
|
| Issuance of Common Stock | 35,425 | 259 | 8,000 | - | 6,000 | - | Upgrade
|
| Other Financing Activities | 596.83 | -3.18 | -0 | - | - | - | Upgrade
|
| Financing Cash Flow | 35,959 | 200.03 | 7,896 | -232.1 | 24,289 | -183.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 4.48 | 4.09 | - | 40.44 | 218.5 | - | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | -0 | - | - | 0 | Upgrade
|
| Net Cash Flow | 4,507 | -12,731 | -5,773 | -9,590 | 24,293 | 5,978 | Upgrade
|
| Free Cash Flow | -18,632 | -14,750 | -8,766 | -15,337 | -2,078 | -10,322 | Upgrade
|
| Free Cash Flow Margin | -2603.11% | -2253.53% | -7968.93% | -198.32% | -5779.96% | -412888.34% | Upgrade
|
| Free Cash Flow Per Share | -278.52 | -261.96 | -167.13 | -294.29 | -44.72 | -2231.70 | Upgrade
|
| Cash Income Tax Paid | 341.11 | -11.04 | 50.18 | 15.8 | 15.98 | -44.07 | Upgrade
|
| Levered Free Cash Flow | - | -10,722 | -4,331 | -11,188 | 2,384 | -5,919 | Upgrade
|
| Unlevered Free Cash Flow | - | -10,718 | -4,329 | -11,188 | 2,384 | -5,919 | Upgrade
|
| Change in Working Capital | 647.89 | -5,034 | 104.56 | -6,116 | 6,591 | 288.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.